Compare RYZ & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | MDXG |
|---|---|---|
| Founded | 1842 | 2006 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 530.2M |
| IPO Year | 2014 | 2007 |
| Metric | RYZ | MDXG |
|---|---|---|
| Price | $28.30 | $3.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 349.5K | ★ 1.5M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $75.79 | N/A |
| Revenue Next Year | $2.17 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $19.34 | $3.03 |
| 52 Week High | $29.03 | $7.99 |
| Indicator | RYZ | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 60.96 | 51.81 |
| Support Level | $23.47 | $3.45 |
| Resistance Level | $29.03 | $3.80 |
| Average True Range (ATR) | 1.15 | 0.12 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 88.90 | 65.71 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.